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Purpose: The purpose of this research is to study drug use during pregnancy in Sweden and 
agreement between use according to antenatal medical records and dispensed drugs from a 
pharmacy database.
Patients and methods: From the Swedish Medical Birth Register (MBR), we established a 
population-based cohort of 102,995 women who gave birth in 2007. Using the unique personal 
registration number, information on dispensed drugs from the Prescribed Drug Register (PDR) 
was obtained prior to, during, and after the pregnancies and compared with MBR information 
on drug use from standardized antenatal medical records.
Results: According to the PDR, 57.6% of the 102,995 women filled a prescription with at 
least one drug during pregnancy and 50.9% during the lactating period (until 3 months after 
delivery). The most dispensed drugs during pregnancy were B-lactam antibacterials and 
  penicillins. Agreement between drugs recorded in antenatal medical records and dispensed 
drugs was highest for drugs used for chronic conditions. The agreement was particularly 
high for thyroid therapy (85.3%), anti-intestinal inflammatory drugs (80.3%), antiepileptics 
(69.2%), immunosuppressants (67.4%), and insulin (63.8%). Agreement for drugs used for 
occasional use was generally lower, ranging between 42.5% for antihistamines and 0.8% for 
gynecological anti-infectives.
Conclusions: A large proportion of women filled a prescription during pregnancy or the   lactating 
period. Agreement between drug use in medical antenatal records and register information 
from a national pharmacy database was high for drugs used for chronic conditions but low for 
occasional use. For occasionally used drugs, medical record and register-based data may provide 
incomplete exposure information because of nonreporting or noncompliance.
Keywords: drug utilization, pregnancy, lactation, pharmacoepidemiology
Introduction
Most women use prescribed drugs during pregnancy according to studies from Europe 
and the United States.1–8 Use of drugs during pregnancy is complicated because of 
the limited knowledge with regard to beneficial and possible adverse effects for both 
the mother and the fetus as pregnant women are rarely included in drug trials.
Presumably noncompliance for prescribed drugs during pregnancy is prevalent, but 
as the information on drug use might differ depending on how it was obtained, knowl-
edge about use during pregnancy is still relatively unknown.9,10 In a Danish study, Olesen 
et al compared dispensed drugs from a prescription database with information on intake 
obtained from telephone interviews with pregnant women. The results revealed that 
drugs used for chronic diseases during pregnancy were always reported to be used, Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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which was not the case for local or   short-term used drugs.9 
However, women may report differently to health care person-
nel compared with an interviewer on the telephone, and the 
women who participated in the Danish study may have been 
more ‘compliant’ when compared to nonparticipating women. 
Hence, the results may not be generalized to pregnant women 
in a clinical setting. In Sweden, information on drugs used 
during pregnancy is recorded at first visit to antenatal care 
and throughout pregnancy within the standardized antenatal 
medical record. Since 1994, the information on drug use 
has been forwarded to the Swedish Medical Birth Register 
(MBR), and several studies have used the information in 
the MBR to assess possible adverse effects of drugs used 
during pregnancy despite the limited knowledge concerning 
data validity.11 The aims of the present study were to study 
prescribed dispensed drugs among pregnant and lactating 
women using information from the Swedish Prescribed Drug 
Register (PDR) and to compare this information with drug 
use reported in the standardized medical antenatal records 
and included in the MBR.
Material and methods
Study population
We used the MBR to identify women with singleton births 
between January 1 and December 31, 2007. The MBR 
recorded 102,995 women during the study period, and by 
means of each individual’s unique civil registration number 
(CPR), we linked data from this register with data from 
the PDR12 to identify prescribed dispensed drugs 3 months 
prior to pregnancy until 3 months after delivery. The CPR is 
assigned to all residents in Sweden at birth or immigration.13 
The PDR contains information with unique patient identi-
fiers for all prescriptions dispensed to the whole population 
of Sweden (9 million inhabitants). For prescribed drugs, the 
register includes data on dispensed item, substance, brand 
name, formulation, package size, dispensed amount, dosage, 
expenditure, and reimbursement. There is also information 
on date of prescribing and dispensing, as well as prescriber’s 
profession and practice. All drugs are classified according 
to the World Health Organization Anatomical Therapeutic 
Chemical (ATC) classification. There is no information on 
over-the-counter (OTC) medications and for drugs used or 
administered in hospitals.12
The population-based MBR includes prospectively col-
lected information, including demographic data, reproductive 
history, and complications during pregnancy, delivery, and the 
neonatal period among more than 98% of all births in Swe-
den.14 In the MBR, maternal characteristics are recorded in a 
standardized manner during a woman’s first visit for antenatal 
care, which occurs during first the trimester in more than 
95% of the pregnancies. Gestational age was primarily based 
on prenatal ultrasound estimation of last menstrual period 
(LMP) if present, and otherwise estimated on the recorded 
date of the first day of LMP. Ultrasound for determination of 
gestational length has been offered to all pregnant women in 
Sweden since 1990, 95% of whom accept it.15
At first visit to antenatal care, the midwife records 
drugs used during pregnancy. This includes information on 
brand name, formulation, dosage, and gestational week of 
use. At each antenatal visit, the midwife and the attending 
doctor update information on drug use in the standardized 
record, including gestational week at start and end of use. 
The completeness of this information is not known. In the 
MBR, information on drug use is converted into ATC codes. 
Self-reported drug use during pregnancy includes prescribed 
drugs, OTC drugs, natural remedies, and homeopathics.
Dispensed drugs from PDR were described from 
3 months prior to estimated LMP to 3 months postpartum 
for each woman. According to the date of birth and predicted 
time of LMP, each pregnancy was divided into five periods: 
a) prepregnancy (3 months before LMP), b) first trimester 
(0–13 weeks), c) second trimester (14–28 weeks), d) third 
trimester (29 to weeks until delivery), and e) lactation period 
(until 3 months postpartum). Agreement between dispensed 
drugs in the PDR and recorded drug use in MBR until first 
visit to antenatal care was calculated as predictive values 
with 95% confidence intervals (95% CI), presented by ATC 
groups categorized into drugs used for chronic conditions 
and occasional use. Agreement of drug use was defined as 
the proportion of drugs dispensed according to PDR from 
90 days before until date of first visit to antenatal care. The 
mean gestational age at first attendance was 86.7 days, which 
corresponds to gestational week 12. For women who attended 
antenatal care later than 90 days from LMP, the time period 
was extended to include time from LMP to first visit to ante-
natal care. The 90-day period was chosen as prescriptions in 
Sweden are usually collected at 3-month intervals. Using this 
method, we obtained complete information on drugs used for 
both chronic conditions and occasional use.
We also analyzed the proportion of women with reported 
drug use by ATC category until first attendance at antenatal 
care in the MBR compared to drugs recorded in the PDR 
between 90 and 180 days before first attendance at ante-
natal care.
All analyses were conducted using SAS software, 
version 9.2 (SAS Institute, Inc, Cary, NC, USA).Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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The study was approved (no. 2008/1182-31/4) by one of 
the regional ethical review boards in Stockholm, Sweden.
Results
A total of 102,995 women with singleton births was 
registered in the MBR during 2007. Among these women, 
57.6% (n = 59,281) purchased at least one prescribed drug 
during pregnancy and 50.9% during the lactating period 
(until 3 months after delivery, Table 1). The most widely 
purchased drugs during preconception were antibacterials 
for systemic use (J01) followed by sex hormones (G03), 
NSAIDs (M01A), antidepressants (N06A), and drugs for 
the respiratory system (R). For most ATC categories, there 
was a decrease in the proportion of women who purchased at 
least one prescribed drug during pregnancy. More than half 
of all women (n = 52,425) collected at least one prescribed 
drug during the lactation period (Table 1).
Table 2 presents agreement between drug use recorded in 
the PDR from 90 days before until the first visit to antenatal 
care and drug use reported in MBR. In general, agreement 
was higher for drugs used for chronic conditions compared 
with drugs used more occasionally. Among chronic condi-
tions, the best agreement (85.3%) was found for thyroid 
therapy (H03) followed by anti-intestinal inflammatory 
(A07E), antiepileptic (N03), and immunosuppressant drugs 
(L04), and insulin (A10A). The best agreement for drugs 
used more occasionally was 42.5% for antihistamines (R06). 
Only 7 out of 840 with dispensed gynecological anti-infective 
drugs had their drugs reported in the MBR (Table 2).
Table 3 presents the number and proportion of women 
with reported drug use according to MBR, also registered in 
the PDR from 90 and from 180 days prior to first visit to ante-
natal care. Among 470 women who used insulin according 
to antenatal medical records, 376 (80.0%) had filled a pre-
scription within 90 days before first visit to antenatal care 
and 434 (92.3%) within 180 days before the visit (Table 3). 
More than 7 out of 10 women who used antiepileptics (N03), 
thyroid therapy (H03), antipsychotics (N05A), immunosup-
pressants (N06A), or antidepressants (N06A) were registered 
in the PDR within 90 days before their first visit to antenatal 
care. The lowest agreement between drug use reported in the 
antenatal medical records and information from the PDR 
was found for ophthalmologicals (S01) and antifungals for 
dermatological use (D01A) (Table 3).
Discussion
In the present study, we found that use of prescribed drugs 
during pregnancy is prevalent in Sweden with a large 
variation during pregnancy and lactation periods. The 
agreement between drug use registered in the MBR and 
filled prescriptions recorded in the PDR was high for drugs 
used for chronic conditions, but not for drugs used more 
occasionally. As the information in the MBR is based on 
self-reported drug use and recorded in the antenatal medical 
records and the information in the PDR reflects filled pre-
scriptions, the low agreement for occasionally used drugs 
between the two registers may reflect both nonreporting and 
noncompliance. Consequently, for occasionally used drugs, 
neither of the registers is more advantageous than the other 
as the only source of information for drug exposure, and for 
future studies, presumably the combined information will 
be the best estimate.
In the study by Olesen et al based on telephone interviews 
during pregnancy, agreement was high for drugs used for 
chronic diseases like beta-blockers, insulin, and thyroid 
therapy, which is similar to our findings.9 Previous studies 
have found that low socioeconomic status is associated with 
use of prescription medication during pregnancy, and as indi-
viduals with low socioeconomic status may be less prone to 
participate in surveys, the results from the Danish study may 
not be applicable to pregnant women in general or women 
with low socioeconomic status in particular.4,16
When information on drug use is obtained from inter-
views in surveys or in the clinical setting, the type of drug 
might influence recall accuracy. For drugs used more occa-
sionally, there is a possibility that a woman fails to report 
drug use or prefers not reporting it to the midwife because she 
considers it to be of no importance or because she might fear 
that reporting the drug intake may complicate her pregnancy. 
A Dutch study concluded that interview data will outweigh 
data from pharmacy records for self-medication and compli-
ance, whereas pharmacy records will give better information 
in case of long recall periods and in patients with multiple 
and repeated drug use.10
An additional and complicating aspect when estimating 
drug use from filled prescriptions is the time that might pass 
between drug purchase and medication start. Generally, 
in Sweden, a prescription will cover a period of 90 days. 
However, when we expanded the time period to include 
prescriptions filled up to 180 days prior to the first antenatal 
care visit, we found a better agreement between the infor-
mation obtained from self-reported use and recorded in the 
MBR and the information on purchased drugs from the PDR, 
indicating a delay in starting a medication or using a lower 
dose than prescribed. We are not able to address whether 
this delay or altered dosing is the normal pattern of use of Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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Table 1 number and proportion of women with dispensed drugs from 3 months prior to pregnancy until 3 months postpartum 
according to the Prescribed Drug register among 102,995 women delivered in Sweden, 2007
ATC category Until 3 months  
before pregnancy
First  
trimester
Second  
trimester
Third  
trimester
Lactation period 
0–3 months 
N % N % N % N % N %
Alimentary tract and metabolism (A) 4510 4.38 5305 5.15 4324 4.20 4099 3.98 4695 4.56
Antacids and drugs for peptic ulcer (A02) 1524 1.48 1713 1.66 1220 1.18 1213 1.18 668 0.65
Propulsive (A03) 286 0.28 938 0.91 389 0.38 123 0.12 202 0.20
Anti-intestinal inflammatory drugs (A07E) 304 0.30 291 0.28 284 0.28 265 0.26 242 0.23
insulin (A10A) 392 0.38 527 0.51 654 0.63 884 0.86 392 0.38
Drugs for diabetes (A10B) 215 0.21 121 0.12 14 0.01 8 0.01 28 0.03
Blood and blood-forming organs (B) 2008 1.95 3147 3.06 3457 3.36 3213 3.12 2974 2.89
Antithrombotic agents (B01) 197 0.19 1016 0.99 1215 1.18 1024 0.99 1963 1.91
iron (B03A) 412 0.40 583 0.57 925 0.90 799 0.78 448 0.43
Vitamin B12 and folic acid (B03B) 1312 1.27 1560 1.51 1446 1.40 1467 1.42 503 0.49
Cardiovascular system (C) 1106 1.07 982 0.95 1052 1.02 1612 1.57 3153 3.06
Diuretic (C03) 131 0.13 99 0.10 53 0.05 69 0.07 138 0.13
Beta-blockers (C07) 448 0.43 448 0.43 407 0.40 751 0.73 1198 1.16
Calcium blockers (C08) 54 0.05 35 0.03 51 0.05 100 0.10 178 0.17
Agents acting on the renin–angiotensin  
system (C09)
92 0.09 44 0.04 3 0.003 5 0.005 132 0.13
Dermatologicals (D) 3789 3.68 3452 3.35 3246 3.15 2498 2.43 4428 4.30
Antifungals for dermatological use (D01A) 749 0.73 815 0.79 799 0.78 555 0.54 2065 2.00
Antibiotics and chemotherapy for  
dermatological use (D06)
298 0.29 224 0.22 176 0.17 137 0.13 298 0.29
Dermal corticosteroids (D07) 1808 1.76 1540 1.50 1521 1.48 1099 1.07 1388 1.35
Antiacne preparations (D10) 531 0.52 428 0.42 265 0.26 137 0.13 152 0.15
genitourinary system and sex hormones (g)10,920 10.60 5624 5.46 1488 1.44 1012 0.98 24,365 23.66
gynecological anti-infectives (g01) 623 0.60 1038 1.01 1291 1.25 902 0.88 323 0.31
Other gynecologicals (g02) 610 0.59 137 0.13 10 0.01 13 0.01 2103 2.04
Sex hormones (g03) 9846 9.56 4509 4.38 152 0.15 63 0.06 22,569 21.91
Systemic hormonal preparations (h) 3666 3.56 3047 2.96 2758 2.68 2515 2.44 6015 5.84
Corticosteroids for systemic use (h02) 907 0.88 585 0.57 394 0.38 315 0.31 631 0.61
Thyroid therapy (h03) 1742 1.69 2102 2.04 2349 2.28 2187 2.12 1867 1.81
Anti-infectives for systemic use (  J) 11,622 11.28 10,835 10.52 11,492 11.16 10,506 10.20 14,897 14.46
Antibacterials for systemic use (  J01) 10,015 9.72 10,012 9.72 11,081 10.76 9720 9.44 14,183 13.77
Tetracyclines (  J01A) 1549 1.50 674 0.65 75 0.07 18 0.02 475 0.46
B-lactam antibacterials and penicillins (  J01C) 5867 5.70 6664 6.47 7810 7.58 6496 6.31 9123 8.86
Other B-lactams (  J01D) 735 0.71 982 0.95 1442 1.40 1368 1.33 3983 3.87
Sulfonamides and trimethoprim (  J01E) 903 0.88 376 0.37 86 0.08 99 0.10 827 0.80
Macrolides, lincosamides, and  
streptogramins (  J01F)
771 0.75 414 0.40 425 0.41 388 0.38 964 0.94
Quinolones (  J01M) 812 0.79 310 0.30 34 0.03 27 0.03 197 0.19
Other antibacterials (  J01X) 546 0.53 1624 1.58 2515 2.44 2324 2.26 380 0.37
Antimycotics for systemic use (  J02) 1160 1.13 503 0.49 182 0.18 186 0.18 818 0.79
Antiviral therapy (  J05A) 627 0.61 375 0.36 222 0.22 720 0.70 278 0.27
Antineoplastic and immunomodulating  
agents (L)
1709 1.66 531 0.52 98 0.10 88 0.09 149 0.14
immunosuppressant (L04) 135 0.13 109 0.11 86 0.08 78 0.08 117 0.11
Musculoskeletal system (M) 3784 3.67 1522 1.48 488 0.47 238 0.23 7408 7.19
nSAiD (M01A) 3520 3.42 1315 1.28 350 0.34 163 0.16 7272 7.06
Muscle relaxants (M03) 251 0.24 126 0.12 99 0.10 49 0.05 58 0.06
nervous system (n) 7494 7.28 6086 5.91 4849 4.71 4464 4.33 8071 7.84
Opioids (n02A) 1791 1.74 1461 1.42 1754 1.70 1919 1.86 3362 3.26
Analgetics (n02B) 1551 1.51 1312 1.27 1289 1.25 1132 1.10 3233 3.14
Antimigraine (n02C) 825 0.80 521 0.51 260 0.25 149 0.14 209 0.20
(Continued)Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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prescribed drugs among women in reproductive age or if it 
was the pregnancy per se that influenced drug use.
Drug use during pregnancy is complicated by the 
potential risk for both mother and fetus. For women with 
chronic inflammatory disease like rheumatoid arthritis 
and inflammatory bowel disease, use of medications like 
methotrexate is clearly teratogenic, whereas there is a lack 
of knowledge concerning the safety of TNF-alpha-blockers 
during pregnancy.17 We observed that corticosteroids for 
systemic use and immunosuppressant drugs were dispensed 
less during pregnancy compared to the 3-month period before 
pregnancy. As knowledge concerning adverse fetal effects 
of these drugs in humans is limited and serious adverse 
effects have been reported in animal studies, the precaution 
of reducing or avoiding systemic anti-inflammatory medica-
tion during pregnancy might be wise.18–20 On the other hand, 
unless pregnancy in itself reduces disease activity, stopping or 
reducing medication might increase risk of flares and worsen-
ing of the disease, which may also affect the fetus adversely. 
Agreement between self-reported and dispensed drugs was 
high for immunosuppressant therapy, whereas this was not 
found for systemic corticosteroid use. For thyroid therapy, on 
the other hand, use increased during pregnancy, and there was 
good agreement between self-reporting and expenditure data. 
These findings are in line with drug use during pregnancy 
in Denmark, with agreements of 100% and 20% for thyroid 
drugs and systemic corticosteroids, respectively.9
For studies on congenital abnormalities (CA), time of 
exposure is of importance because the period of teratogenesis 
may be quite short. There is a risk that studies based on 
linkage with prescription registers will be uncertain. This 
is less important for chronically used drugs compared with 
occasionally used drugs like antibiotics and sedatives.21 In 
addition, a teratogen does not uniformly increase the rates 
of all CA, but rather tends to increase rates of selected CA, 
which further emphasizes valid drug exposure information.22 
Our finding of a low agreement between self-reported drug 
used as recorded in the MBR and purchased drugs recorded 
in the PDR for occasionally used drugs emphasizes the dif-
ficulties in using such information when studying these drugs 
in association with rare outcomes such as CA.23,24
Antibiotics were the most dispensed prescribed drug dur-
ing pregnancy, and the proportion of women filling prescrip-
tions with antibiotics increased further during the lactating 
period reaching almost 14%. The most prescribed antibiotic 
drugs were B-lactam antibacterials and penicillins, and we 
observed strong decline in dispensed antibiotics not recom-
mended during pregnancy. Similar findings were reported in 
a Norwegian5 and a German25 study. Among women with a 
dispensed antibiotic drug from 90 days before first visit to 
antenatal care, only 20% reported this intake according to the 
medical records. Conversely, among women who reported use 
of antibiotics, 83% were dispensed according to the register 
within 90 days from first attendance at antenatal care.
The use of drugs for the nervous system decreased during 
pregnancy except for antipsychotics (N05A), where there was 
a strong increase in dispensed drugs during first trimester. 
Similar findings were reported from Norway.5 The safety 
Table 1 (Continued)
ATC category Until 3 months  
before pregnancy
First  
trimester
Second  
trimester
Third  
trimester
Lactation period 
0–3 months 
N % N % N % N % N %
Antiepileptics (n03) 337 0.33 308 0.30 261 0.25 244 0.24 307 0.30
Antipsychotics (n05A) 194 0.19 677 0.66 189 0.18 64 0.06 114 0.11
Sedatives (n05B) 1001 0.97 569 0.55 224 0.22 160 0.16 578 0.56
hypnotics (n05C) 1193 1.16 764 0.74 498 0.48 555 0.54 556 0.54
Antidepressants (n06A) 3102 3.01 2062 2.00 1257 1.22 1029 1.00 1653 1.60
Antiparasitic products, insecticides  
and repellents (P)
1223 1.19 472 0.46 238 0.23 158 0.15 2690 2.61
respiratory system (r) 7761 7.54 13,050 12.67 12,214 11.86 10,747 10.43 5450 5.29
nasal preparations (r01) 2936 2.85 2930 2.84 4081 3.96 3369 3.27 1453 1.41
Antiasthmatics (r03) 2226 2.16 2294 2.23 2711 2.63 2524 2.45 1556 1.51
Cough and cold preparations (r05) 2378 2.31 2599 2.52 3481 3.38 3030 2.94 1470 1.43
Antihistamines (r06) 2316 2.25 7727 7.50 4721 4.58 3868 3.76 2011 1.95
Sensory organs (S) 2340 2.27 2011 1.95 1895 1.84 1508 1.46 1986 1.93
Ophthalmologicals (S01) 1790 1.74 1513 1.47 1452 1.41 1157 1.12 1533 1.49
Total 37,277 36.19 36,167 35.12 32,002 31.07 29,572 28.71 52,267 50.75
Abbreviations: ATC, Anatomical Therapeutic Chemical; NSAID, nonsteroidal anti-inflammatory drug.Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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Table 2 Number of women with dispensed prescribed drugs according to the PDR from 90 days before first visit to antenatal care,1 
number of women who reported drug use according to the MBr, and the predictive value of reporting drug use in MBr after a 
dispensed prescription in Sweden, 2007
ATC category PDR PDR and MBR Agreement
N N % 95% CI
Chronic conditions
  Thyroid therapy (h03) 1776 1515 85.3 (83.6–86.9)
  Anti-intestinal inflammatory drugs (A07E) 274 220 80.3 (75.1–84.8)
  Antiepileptics (n03) 302 209 69.2 (63.7–74.4)
  immunosuppressant (L04) 98 66 67.4 (57.1–76.5)
  insulin (A10A) 589 376 63.8 (59.8–67.7)
  Beta-blockers (C07) 407 259 63.6 (58.7–68.3)
  Antidepressants (n06A) 2225 1331 59.8 (57.7–61.9)
  Antiasthmatics (r03) 2123 1226 57.8 (55.6–59.9)
  Antipsychotics (n05A) 479 232 48.4 (43.9–53.0)
  Diuretic (C03) 104 44 42.3 (32.7–52.4)
  Calcium blockers (C08) 39 15 38.5 (23.4–55.4)
  Analgetics (n02B) 1361 318 23.4 (21.1–25.7)
  Opioids (n02A) 1460 314 21.5 (19.4–23.7)
  Antimigraine (n02C) 570 122 21.4 (18.1–25.0)
  Corticosteroids for systemic use (h02) 652 79 12.1 (9.7–14.9)
  nSAiD (M01) 1843 172 9.3 (8.0–10.8)
Occasional use
  Antihistamines (r06) 5625 2392 42.5 (41.2–43.8)
  Propulsive (A03) 706 215 30.5 (27.1–34.0)
  Antacids and drugs for peptic ulcer (A02) 1552 436 28.1 (25.9–30.4)
  hypnotics (n05C) 829 205 24.7 (21.8–27.8)
  Antibacterials for systemic use (  J01) 9493 1946 20.5 (19.7–21.3)
  Sedatives (n05B) 658 132 20.1 (17.1–23.3)
  Antiviral therapy (  J05A) 400 74 18.5 (14.8–22.7)
  nasal preparations (r01) 2733 441 16.1 (14.8–17.6)
  Sex hormones (g03) 5096 523 10.3 (9.4–11.1)
  Ophthalmologicals (S01) 1522 95 6.2 (5.1–7.6)
  Antimycotics for systemic use (  J02) 671 38 5.7 (4.0–7.7)
  Dermal corticosteroids (D07) 1515 81 5.4 (4.3–6.6)
  Antifungals for dermatological use (D01A) 753 19 2.5 (1.5–3.9)
  gynecological anti-infectives (g01) 840 7 0.8 (0.3–1.7)
Notes: 1For women who attended antenatal care later than 90 days from last menstrual period, the time period was extended to include time from last menstrual period 
to first visit to antenatal care.
Abbreviations:  ATC,  Anatomical  Therapeutic  Chemical;  NSAID,  nonsteroidal  anti-inflammatory  drug;  CI,  confidence  interval;  PDR,  Prescribed  Drug  Register;   
MBr, Medical Birth register.
of antipsychotics during pregnancy remains unclear, but 
women who discontinue treatment during pregnancy have 
an increased risk of relapse.26 Antipsychotic use during preg-
nancy has been associated with increased risk of CA27 and 
preterm delivery, whereas risks of low birth weight and small-
for-gestational-age birth were not influenced by antipsychotic 
use in a large Taiwan study.26
A major strength of the present study is the use of a 
population-based cohort comprising almost all deliveries in 
Sweden in 2007. Data from the PDR contains all expendi-
tures of prescribed drugs in pharmacies in Sweden. Hence, 
we have an almost complete coverage of prescribed drugs 
dispensed during pregnancy. Information in the MBR on drug 
use and maternal characteristics is prospectively reported in 
early pregnancy, and consequently, the risk of recall bias is 
limited.
A limitation of this study is the lack of information on 
drugs used in hospitals. Hence, there may be an underreport-
ing of drugs administrated by infusion and drugs for chronic 
psychiatric and rheumatic disease. However, this would most 
likely influence the findings for chronic conditions and not for 
occasional use. Furthermore, we do not have any information 
in the PDR on OTC drugs, and the low compliance between 
self-reported and register information on, for example, NSAID 
and analgetics may stem from OTC drugs or from drugs dis-
pensed by the partner or other bound to share medication. In 
the present study, we included only women with a delivery from 
gestational week 22 and onward, and consequently, we were not Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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able to study drug use in relation to miscarriage or terminations 
of pregnancies because of suspected malformations or drug 
use in early pregnancy. In addition, we chose to include only 
women giving birth to singletons, as pregnancies with more 
than one fetus, in general, are under closer surveillance with 
higher risks of drug treatment and women giving birth to more 
than one infant will be less prone to breast-feed, which might 
affect their drug intake. Accordingly, the results from this study 
reflect only women giving birth to singletons.
Conclusion
In conclusion, we found that a large proportion of women 
in Sweden collected a dispensed drug during pregnancy and 
the lactating period. Agreement between drug use in medical 
records at antenatal care and register information was high 
for drugs used for chronic conditions but low for occasional 
use. Consequently, for occasionally used drugs, both medical 
record and register data may provide incomplete exposure 
information because of nonreporting or noncompliance.
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Table 3 number and proportion of women who reported drug use according to the MBr and dispensed prescribed drugs in the PDr 
90 and 180 days before first visit to antenatal care in Sweden, 2007
ATC category MBR PDR and  
MBR 90 days
Proportion in PDR  
within 90 days
PDR and  
MBR 180 days
Proportion in PDR 
within 180 days
N N % 95% CI N % 95% CI
Chronic conditions
  insulin (A10A) 470 376 80.0 (76.1–83.5) 434 92.3 (89.6–94.6)
  Antiepileptics (n03) 269 209 77.7 (72.2–82.6) 238 88.5 (84.0–92.0)
  Thyroid therapy (h03) 1919 1515 78.9 (77.1–80.8) 1751 91.3 (90.0–92.5)
  Antipsychotics (n05A) 303 232 76.6 (71.4–81.2) 246 81.2 (76.3–85.4)
  immunosuppressant (L04) 91 66 72.5 (62.2–81.4) 81 89.0 (80.7–94.6)
  Antidepressants (n06A) 1861 1331 71.5 (69.4–73.6) 1640 88.1 (86.6–89.6)
  Beta-blockers (C07) 373 259 69.4 (64.5–74.1) 298 79.9 (75.5–83.8)
  Diuretic (C03) 66 44 66.7 (54.0–77.8) 55 83.3 (72.1–91.4)
  Antimigraine (n02C) 200 122 61.0 (53.9–67.8) 150 75.0 (68.4–80.8)
  Calcium blockers (C08) 26 15 57.7 (36.9–76.6) 20 76.9 (56.4–91.0)
    Anti-intestinal inflammatory  
drugs (A07E)
391 220 56.3 (51.2–61.2) 265 67.8 (62.9–72.4)
  Opioids (n02A) 576 314 54.5 (50.3–58.6) 364 63.2 (59.1–67.1)
  Antiasthmatics (r03) 2977 1226 41.2 (39.4–43.0) 1612 54.2 (52.3–56.0)
  Corticosteroids for systemic use (h02) 260 79 30.4 (24.9–36.4) 98 37.7 (31.8–43.9)
  nSAiD (M01) 1254 172 13.7 (11.9–15.7) 244 19.5 (17.3–21.8)
  Analgetics (n02B) 6669 318 4.8 (4.3–5.3) 442 6.6 (6.0–7.3)
Occasional use
  Antibacterials for systemic use (  J01) 2342 1946 83.1 (81.5–84.6) 1989 84.9 (83.4–86.4)
  Propulsive (A03) 292 215 73.6 (68.2–78.6) 226 77.4 (72.2–82.1)
  Antiviral therapy (  J05A) 112 74 66.1 (56.5–74.8) 84 75.0 (65.9–82.7)
  Sex hormones (g03) 819 523 63.9 (60.5–67.2) 605 73.9 (70.7–76.9)
  Sedatives (n05B) 213 132 62.0 (55.1–68.5) 160 75.1 (68.8–80.8)
  hypnotics (n05C) 333 205 61.6 (56.1–66.8) 240 72.1 (66.9–76.8)
  Antimycotics for systemic use (  J02) 61 38 62.3 (50.0–74.4) 46 75.4 (62.7–85.5)
  gynecological anti-infectives (g01) 17 7 41.2 (18.4–67.1) 7 41.2 (18.4–67.1)
  Antihistamines (r06) 6007 2392 39.8 (38.6–41.1) 2564 42.7 (41.4–43.9)
  Dermal corticosteroids (D07) 220 81 36.8 (30.4–43.6) 113 51.4 (44.6–58.1)
  nasal preparations (r01) 1257 441 35.1 (32.4–37.8) 537 42.7 (40.0–45.5)
    Antacids and drugs for  
peptic ulcer (A02)
1332 436 32.7 (30.2–35.3) 515 38.7 (36.0–41.3)
  Ophthalmologicals (S01) 295 95 32.2 (26.9–37.9) 105 35.6 (30.1–41.3)
    Antifungals for dermatological  
use (D01A)
129 19 14.7 (9.1–22.0) 23 17.8 (11.7–25.5)
Abbreviations: ATC, Anatomical Therapeutic Chemical; NSAID, nonsteroidal anti-inflammatory drug; PDR, Prescribed Drug Register; MBR, Medical Birth Register.Clinical Epidemiology
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